From Mankind to Alkem, top five pharma firms hit by the ban on FDCs

These drugs were found to be irrational and without therapeutic justification

drugs, generics, drug, pharma, pharmaceuticals, medicines, tablets, capsules, healthcare, IPR — Some major Western concerns about India's patent framework are the definitions of inventions and provisions for compulsory licensing

Last Updated : Sep 17 2018 | 11:45 PM IST

The health ministry last week banned 328 fixed dose combination drugs (FDCs) following recommendations of the drug technical advisory board. These drugs were found to be irrational and without therapeutic justification. Also, manufacture and sale of six other FDCs has been regulated. Fifteen FDCs have been exempted from the ban in accordance with the order of the SC.

Here’s the lowdown on its impact on pharma firms:

Annual domestic pharmaceutical market size: Rs 1.24 trillion

Market size of 328 banned FDCs: Rs 10.40 billion which is 0.8% of the total